Loading...
•
Jun 30, 2024
Mural Oncology Q2 2024 Earnings Report
Mural Oncology announced second quarter 2024 financial results and provided an update on pipeline progress.
Key Takeaways
Mural Oncology reported a net loss of $31.6 million for the second quarter of 2024, with cash, cash equivalents, and marketable securities totaling $204.7 million as of June 30, 2024. The company reaffirms its cash runway guidance into the fourth quarter of 2025 and anticipates readouts from nemvaleukin alfa in two late-stage clinical trials in the first half of 2025.
Mural appointed George Golumbeski, Ph.D., to its board of directors in July.
Late-stage clinical trials of nemvaleukin alfa continue to progress toward readouts in the first half of 2025, focusing on two foundational indications.
Candidate nominations for Mural’s IL-18 and IL-12 programs are expected later this year.
Company reaffirms guidance that its cash, cash equivalents, and marketable securities are expected to fund its operations into the fourth quarter of 2025.
Forward Guidance
The company reaffirms guidance that its cash, cash equivalents, and marketable securities are expected to fund its operations into the fourth quarter of 2025. Management forecasts lower operating expenses in 2025 versus 2024 due to the timing of clinical trial expenses.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...